



Ivane Kiladze, MD. PhD

Nationality: Georgian | **Gender:** Male |
ivane6@hotmail.com | ivane.kiladze@iliauni.edu.ge

WORK EXPERIENCE

01/12/2020 – CURRENT – Tbilisi, Georgia

HEAD OF MEDICAL ONCOLOGY DEPARTMENT – CMC-CAUCASUS MEDICAL CENTRE

15/09/2016 – 01/12/2020 – Tbilisi, Georgia

HEAD OF THE ONCOLOGY AND HEMATOLOGY DEPARTMENT – RESEARCH INSTITUTE OF CLINICAL MEDICINE AFTER AC. F.TODUA

09/01/2009 – 14/09/2016 – Tbilisi, Georgia

HEAD OF ONCOLOGY DEPARTMENT – AVERSI HOSPITAL

01/09/2012 – 01/07/2014 – Tbilisi, Georgia

DOCTOR-ONCOLOGIST – S.KHECHINASHVILI UNIVERSITY HOSPITAL. BREAST CANCER UNIT

04/01/2011 – 01/08/2011 – Tbilisi, Georgia

MEDICAL ONCOLOGIST – THE UNIVERSITY CLINIC. DEPARTMENT OF RADIO-ONCOLOGY

01/01/2008 – 01/01/2009 – Kutaisi, Georgia

MEDICAL ONCOLOGIST – SURGICAL CENTRE AFTER ST. NIKOLOZI

01/09/2006 – 01/08/2007 – Saint-Petersburg, Russia

DOCTOR-ONCOLOGIST – N.N PETROV ONCOLOGY RESEARCH INSTITUTE. DEPARTMENT OF ONCO-SURGERY

EDUCATION AND TRAINING

04/2018 – 05/2019 – Rämistrasse 71, 8006 Zürich, Switzerland, Zurich, Switzerland

ZURICH UNIVERSITY AND ESO CERTIFICATE OF ADVANCED STUDIES IN LUNG CANCER PROGRAMME – University of Zurich and ESO

10/2009 – 12/2009 – Weismann St. 6, Tel-Aviv, Israel

OBSERVERSHIP – Tel-Aviv Sourasky Medical Center

03/2007 – 05/2007 – Saint-Petersburg, Russia

OBSERVERSHIP – St.Giorgi Hospital

01/10/2003 – 01/06/2006 – Leningradskaya Str., 68, Saint-Petersburg, Russia

DOCTOR- ONCOLOGIST. POSTGRADUATE STUDY, M.D IN ONCOLOGY (DIPLOMA# A 2524156) – N. N. Petrov Research Institute of Oncology

2001 – 2001 – Ankara, Turkey

OBSERVERSHIP – Hacettepe University Hospital

01/09/1997 – 01/06/2003 – 33 Vazha Pshavela Ave, Tbilisi, Georgia

DIPLOMA OF MEDICAL DOCTOR (DIPLOMA # 103098) – Tbilisi State Medical University

<https://tsmu.edu/ts/>

● LANGUAGE SKILLS

Mother tongue(s): **GEORGIAN**

Other language(s):

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken production	Spoken interaction	
ENGLISH	C1	C1	B2	B2	B2
RUSSIAN	C2	C2	C1	C1	C1
ITALIAN	A1	A1	A1	A1	A1

Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user

● PUBLICATIONS

Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients Receiving Oxaliplatin-Based Combination Chemotherapy- CapeOX

I.Kiladze, N. Sharikadze, T. Esakia.

<https://doi.org/10.1093/annonc/mdw370.52> – 2016

Annals of Oncology, Volume 27, Issue suppl_6, 1 October 2016, 504P

Breast Cancer Subtypes in Young Adult Women in Georgia. The Breast.

I. Kiladze, A. Mariamidze, M. Mchedlishvili, K. Tsomaia
2016

Comparison of Breast Cancer subtypes between young and elderly women. Annals of Oncology, Volume 28, Issue suppl_5, 1 September 2017,

I. Kiladze, A. Mariamidze, M. Mchedlishvili, K. Tsomaia, F. Todua

[https://www.annalsofoncology.org/article/S0923-7534\(20\)38954-7/fulltext](https://www.annalsofoncology.org/article/S0923-7534(20)38954-7/fulltext) – 2017

Paclitaxel every-3-weeks versus weekly Paclitaxel and versus weekly vinorelbin in metastatic Breast cancer.

L. Katselashvili, I. Kiladze, M. Katcharava, N. Jokhadze, T. Melkadze , A. Matitashvili et al.

<https://doi.org/10.1093/annonc/mdx365.068> – 2017

Annals of Oncology, Volume 28, Issue suppl_5, 1 September 2017, mdx365.068

Primary surgery followed by chemotherapy versus definitive concurrent chemoradiotherapy in locally advanced nonsmall cell lung cancer.

I. Kiladze, V. Kuchava, N. Joxadze, L. Katselashvili, T. Melkadze

[http://www.jto.org/article/S1556-0864\(18\)30395-2/pdf/](http://www.jto.org/article/S1556-0864(18)30395-2/pdf/) – 2018

Journal of Thoracic Oncology. **April 2018**. Volume 13, Issue 4, Supplement, Pages S66–S67

Optimal chemotherapy regimen for concurrent chemo-radiotherapy of locally advanced unresectable stage III non-small cell lung cancer (NCSLC).

N. Jokhadze, I. Kiladze, L. Katselashvili et al.

[http://www.jto.org/article/S1556-0864\(18\)30394-0/fulltext](http://www.jto.org/article/S1556-0864(18)30394-0/fulltext) – 2018

Journal of Thoracic Oncology. Vol. 13 No. 4S: S66–S67

Randomized Prospective Study: Paclitaxel every-3-weeks versus weekly Paclitaxel and versus weekly Vinorelbin in metastatic Breast cancer.

L. Katselashvili, I. Kiladze, M. Katcharava, N. Jokhadze et al.

[https://www.thebreastonline.com/article/S0960-9776\(17\)30697-5/fulltext](https://www.thebreastonline.com/article/S0960-9776(17)30697-5/fulltext) – 2018

The Breast

Perioperative chemotherapy with FLOT versus other regimens for resectable gastric cancer

T. Esakia, B. Metonidze, L Turkiashvili, E. Dgebuadze, L. Katselashvili, T. Melkadze, I. Kiladze

<https://doi.org/10.1093/annonc/mdz155.219> – 2019

Annals of Oncology. Volume 30 | Supplement 4 | July 2019

N. Jankarashvili, M. Topeshashvili, L. Turkiashvili, B. Metonidze, I. Kiladze

[https://doi.org/10.1016/S0167-8140\(18\)31779-1](https://doi.org/10.1016/S0167-8140(18)31779-1)

2018

Neoadjuvant VMAT Radiochemotherapy with a SIB compared to Standard chemoradiation for Locally Advanced Rectal Cancer. *Radiotherapy and Oncology*. Supplement 1, S797-S798, April 01, 2018

Optimal Dose of Cisplatin (CDDP) Given Concurrently with Radiotherapy (RT) in Locally Advanced Squamous Cell Head and Neck Cancer (SQC HNC).

Branislav JEREMIC, Pavol DUBINSKY, Marta JEREMIC, Ivane KILADZE, Gökhan ÖZYIGIT

http://onkder.org/pdf/pdf_TOD_1138.pdf – 2020

Turkish Journal of Oncology

Lung Cancer in Georgia.

Ivane Kiladze, Elene Mariamidze, Branislav Jeremic

doi.org/10.1016/J.JTHO.2020.02.030 – 2020

Journal of Thoracic Oncology Vol. 15 No. 7: 1113-1118.

Radiotherapy target volume for limited disease small cell lung cancer: good news from dark side of moon.

Branislav Jeremic, Ivane Kiladze, Marta Jeremic, Nenad Filipovic.
<https://atm.amegroups.com/article/view/39550/html> – 2020
Annals of Translational Medicine. [Vol 8, No 14 \(July 2020\)](#)

Challenging pretreatment aspects of lung cancer in Georgia

I. Kiladze, E. Mariamidze, B. Jeremic
<https://www.lungdiseasesjournal.com/articles/challenging-pretreatment-aspects-of-lung-cancer-in-georgia.html> – 2020

Journal of Lung Health and Diseases

<https://www.lungdiseasesjournal.com/articles/challenging-pretreatment-aspects-of-lung-cancer-in-georgia.html>

Neoadjuvant Treatment for Resectable, Stage IIIA Non-Small Cell Lung Cancer

Ivane Kiladze, Merab Kiladze, Branislav Jeremic
[10.19080/CTOIJ.2021.17.555973](https://doi.org/10.19080/CTOIJ.2021.17.555973) – 2021
Cancer Therapy and Oncology International Journal CTOIJ (Volume 17 Issue 5)

Novel Technological Aspects of Radiation Therapy in Head and Neck Cancer

Branislav JERICIC, Ivane KILADZE Gökhan ÖZYİĞİT, Nenad FILIPOVIĆ, Pavol DUBINSKY
<https://onkoloji.dergisi.org/abstract.php?id=1213> – 2021
Turk J Oncol 2021;36(2):236–46
<https://onkoloji.dergisi.org/abstract.php?id=1213>

Neuroendocrine pancreatic tumor in a patient with dual diagnosis of tuberous sclerosis complex and basement membrane disease: A case report and review of the literature.

Kopadze, S., Shoshiashvili, I., Dumbadze, A., Tkemaladze, T., & Kiladze, I
<https://doi.org/10.1016/j.radcr.2021.08.041> – 2021
Radiology case reports, 16(11), 3581–3588

Molecular profiling and characteristics of non-small-cell lung cancer patients in Georgia.

Kiladze, I., Mariamidze, E., Baramidze, A., Lomidze, M., Meladze, K., & Jeremic, B
<https://doi.org/10.2217/fon-2021-0177> – 2021
Future oncology (London, England), 17(27), 3585–3594.

Real-World Treatment Patterns of Lung Cancer in a Resource-Restricted Country: The Experience of Georgia

Kiladze I, Mariamidze E, Jeremic B.
<https://journals.sagepub.com/doi/full/10.1177/11786329211055296> – 2021
Health Serv Insights. 2021 Nov 3;14

Radiation Oncology of Lung Cancer: Why We Fail(ed) in Clinical Research?

Jeremić B., Filipović N., Milisavljević S., Kiladze I
https://doi.org/10.1007/174_2021_282 – 2021
Medical Radiology. Springer, Berlin, Heidelberg.

Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Ivane KILADZE, Gökhan ÖZYİĞİT, Pavol DUBINSKY, Nenad FILIPOVIC, Branislav JEREMIC
<http://onkder.org/text.php?id=1281> – 2021
Turk J Oncol 2021;36(4):519–28

Multimodality Treatment of Stage IIIA/N2 NSCLC: Why Always NO to Surgery?

Jeremic B., Kiladze I., Milisavljevic S
https://doi.org/10.1007/174_2021_275 – 2021
Medical Radiology. Springer, Berlin, Heidelberg

Combined Radiation Therapy and Chemotherapy as an Exclusive Treatment Option in Locally Advanced Inoperable Non-small Cell Lung Cancer.

Jeremić B., Dubinsky P., Milisavljević S., Kiladze I.
https://doi.org/10.1007/174_2021_277 – 2021
Medical Radiology. Springer, Berlin, Heidelberg

Role of Thoracic Radiation Therapy in Extensive Disease Small Cell Lung Cancer

Jeremić B., El-Bassiouny M., Ghali R., Kiladze I., Abdel-Wahab S
https://doi.org/10.1007/174_2021_279 – 2021
Medical Radiology. Springer, Berlin, Heidelberg.

Radiation Therapy in Limited Disease Small Cell Lung Cancer.

Jeremić B., Kiladze I., Dubinsky P., Milisavljević S.
https://doi.org/10.1007/174_2021_278 – 2021
Medical Radiology. Springer, Berlin, Heidelberg.

DISTINCT study investigators. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer

Edelman MJ, Dvorkin M, Laktionov K, Kiladze I, Kortua T, Leighl N, Luft A et al
<https://pubmed.ncbi.nlm.nih.gov/35278766/> – 2022
Lung Cancer. 2022 Mar 4;166:135-142.

● **DIGITAL SKILLS**

Microsoft Word | Microsoft Excel | Microsoft Office | Microsoft Powerpoint | Google Drive | Outlook | Facebook | Skype | Zoom

● **MEMBERSHIP**

CURRENT

Member of European Society for Medical Oncology (ESMO)

2009 – CURRENT

Member of ESO

12/2014 – CURRENT

Co-Founder of Association: Georgian Group of Young Oncologists (GYO) and current president

CURRENT

Board member of Georgian Clinical Oncology Association

CURRENT

Member of ESCO Graduate

CURRENT

Member of The International Association for the Study of Lung Cancer (IASLC)

● **PROJECTS**

2021 – 2022

• **A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab vs. placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resec**

Principal Investigator (PI)

2021 – 2022

• **A Phase 2a, Randomized, Double-Blind, PlaceboControlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Acneiform Rash in Subjects with Cancer Receiving EGFRi or MEKi Therapy (ANB019-207)**

Principal Investigator (PI)

2022 – CURRENT

• **“Phase III Study of the study drug versus trabectedin in patients with dedifferentiated (DD) liposarcoma.” RAIN-3201**

Principal Investigator (PI)

2021 – CURRENT

• **A Phase II, Multi-center, Randomized, Open label, two arm Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in patients with Locally Advanced or Metastatic Breast Cancer RP6530-2101**

Principal Investigator (PI)

2020 – 2020

• **PHASE 3. NSCLC NCT03409614 - NSCLC immunotherapy**

Sub-investigator (SI)

2019 – 2020

• **PHASE 3. NSCLC. STUDY R2810-ONC-16113.**

Sub-investigator (SI)

2018 – 2018

• **Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study: Small Cell Lung Cancer - DISTINCT (DIV-SCLC-301) Study**

Principal Investigator (PI)

2014 – 2015

• **Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study: Highly Emetogenic Chemotherapy. HEC Trial. (TS-P04833)**

Principal Investigator (PI)

2014 – 2015

• **Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study: Moderately Emetogenic Chemotherapy. MEC Trial. (TS-P04834)**

Principal Investigator (PI)